SEC Form 4 · accession 0000919574-15-004911
Celator Pharmaceuticals Inc · CPXX
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Scott D Morenstein
Director
Period of report
Jun 11, 2015
Accepted (ET)
Jun 15, 2015 · 1:39 pm EDT
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001327467
Table I — non-derivative securities
No Table I lines on this filing.
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Stock Option (Right to Buy)F3,F1 | $2.60 | Jun 11, 2015 | A | 14,000 | A | — | Jun 11, 2025 | Common Stock | 14,000 | 14,000 | D |
| Stock Option (Right to Buy)F3,F2 | $2.80 | holding | — | — | — | — | Jun 12, 2024 | Common Stock | 14,000 | 14,000 | D |
| Stock Option (Right to Buy)F3,F4 | $3.116 | holding | — | — | — | — | Jun 3, 2023 | Common Stock | 28,000 | 28,000 | D |
| WarrantF3,F5 | $3.58 | holding | — | — | — | — | Apr 29, 2020 | Common Stock | 358 | 358 | D |
| WarrantF6,F5 | $3.58 | holding | — | — | — | — | Apr 29, 2020 | Common Stock | 314,611 | 314,611 | I |
Explanation of responses
- F1The options vest as follows: (i) 4,667 options vest on June 10, 2016; (ii) 1,167 options vest on the 11th day of each of seven consecutive fiscal quarters beginning on September 11, 2016 and continuing through March 11, 2018, and (iii) 1,164 options vest on June 11, 2018.
- F2The options vest as follows: (i) 4,666 options vested on June 12, 2015 and are currently exercisable (ii) 1,166 options vest on the 12th day of each of seven consecutive fiscal quarters beginning on September 12, 2015 and continuing through March 12, 2017; and (iii) 1,172 options vest on June 12, 2017.
- F3These securities are owned by Scott D. Morenstein, who is the Reporting Person.
- F4The options vest as follows: (i) 9,334 options vested on June 3, 2014 and are currently exercisable; (ii) 9,332 vested over four consecutive fiscal quarters beginning on September 3, 2014 through June 3, 2015 and are currently exercisable, (iii) 2,333 options vest on the third day of each of three consecutive fiscal quarters beginning on September 3, 2015 and continuing through March 3, 2016; and (iv) 2,335 options vest on June 3, 2016.
- F5These warrants are currently exercisable.
- F6The reported securities are directly owned by Valence CDK SPV, L.P. ("CDK SPV"). Valence Life Sciences GP II, LLC ("GP II") is the sole general partner of CDK SPV. In his capacity as an advisor to GP II, the reporting person may be deemed to beneficially own securities held by CDK SPV. The reporting person disclaims beneficial ownership of these securities except to the extent of his pecuniary interest therein.